FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2990766679> ?p ?o ?g. }

• W2990766679 abstract "Abstract Background Overexpression of interleukin (IL)-1β has been described in solid tumors, including lung. IL-1β can promote angiogenesis, tumor invasiveness, and induces tumor-associated immunosuppression through myeloid-derived suppressor cell (MDSC) accumulation in tumors. Pre-clinical data has shown that IL-1β inhibition reduced tumor growth, by limiting pro-tumorigenic inflammation and polarization of MDSCs into M1 phenotype. Canakinumab is a human monoclonal antibody with high affinity and specificity for IL-1β. Recently, it was found that canakinumab was associated with a significant and dose-dependent reduction in incidence and mortality from lung cancer based on CANTOS study. Trial design CANOPY-A (NCT03447769) is a phase III, randomized, double-blind, placebo-controlled study designed to evaluate efficacy and safety of adjuvant canakinumab vs placebo in pts with surgically resected NSCLC. This trial will enroll adult pts, with completely resected (R0) AJCC/UICC v.8 stages II-IIIA and IIIB (T > 5 cm and N2) NSCLC, who have completed standard-of-care adjuvant treatments, including cisplatin-based chemotherapy and mediastinal radiation therapy (if applicable). Prior treatment with neoadjuvant chemotherapy or neoadjuvant radiotherapy is not permitted. Approximately 1500 pts will be randomized 1:1 to receive canakinumab (200 mg Q3W, s.c) or placebo (Q3W, s.c.) for 18 cycles or until disease recurrence, unacceptable toxicity, treatment discontinuation at the discretion of the investigator or pt, death, or loss to follow-up. Randomization will be stratified by AJCC/UICC v.8 stage, tumor histology, and region. In the amended protocol, a sub-study was included to determine the biomarker levels in the blood at pre- and post-surgery, and to establish their association with canakinumab efficacy. The primary objective is disease-free survival (per investigator assessment). Secondary objectives include overall survival (key secondary objective), lung cancer-specific survival, safety, pharmacokinetics and immunogenicity of canakinumab, and pt-reported outcomes. Enrollment is ongoing. Clinical trial identification CACZ885T2301. Legal entity responsible for the study Novartis. Funding Novartis. Disclosure B.C. Cho: Honoraria (self): Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD; Advisory / Consultancy: Novartis, AstraZeneca, Boehringer Ingelheim, Roche, BMS, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, MSD; Research grant / Funding (self): Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Dizal Pharma, MSD; Shareholder / Stockholder / Stock options: TheraCanVac Inc; Licensing / Royalties: Champions Oncology. G-C. Chang: Honoraria (self): F. Hoffmann–La Roche, Ltd, Eli Lilly and Company Oncology, AstraZeneca, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, and Merck Sharp & Dohme. Y-C. Kim: Honoraria (self): AstraZeneca, Roche, Boehringer Ingelheim; Research grant / Funding (self): AstraZeneca, Roche, Boehringer Ingelheim. S. Geater: Honoraria (self): AstraZeneca, Boehringer Ingelheim, Roche; Advisory / Consultancy: Boehringer Ingelheim; Research grant / Funding (institution): AstraZeneca, Boehringer Ingelheim, Roche, MSD; Travel / Accommodation / Expenses: AstraZeneca, Boehringer Ingelheim, Roche. S. Saeteng: Honoraria (self): AstraZeneca, Novartis : Speaker. Y. Goto: Speaker Bureau / Expert testimony: AstraZeneca, Eli Lilly, Chugai, Taiho Pharmaceutical, Boehringer Ingelheim, Ono Pharmaceutical, Bristol-Myers Squibb, Pfizer, MSD, Shionogi Pharma, Novartis; Advisory / Consultancy: Eli Lilly, Chugai, Taiho Pharmaceutical, Boehringer Ingelheim, Pfizer, Novartis, AstraZeneca, Glaxo Smith Kline; Research grant / Funding (self): AbbVie, Eli Lilly, Taiho Pharmaceutical, Bristol-Myers Squibb, Ono Pharmaceutical, Daiichi Sankyo, Pfizer, Novartis, Kyorin. S. Lu: Research grant / Funding (self): AstraZeneca, Hutchison, Roche; Advisory / Consultancy: AstraZeneca, Boehringer Ingelheim, Hutchison MediPharma, Simcere, Roche; Honoraria (self): AstraZeneca, Roche. A. Ardizzoni: Advisory / Consultancy: MDS, Roche; Honoraria (self): MSD, BMS, Pfizer, Lilly; Research grant / Funding (self): BMS, Celgene, Roche; Leadership role: Member Educational Committee. F. Barlesi: Honoraria (self): AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly Oncology,. P. De Marchi: Advisory / Consultancy: Roche, Bayer, Msd, BMS, Pfizer, AstraZeneca; Speaker Bureau / Expert Testimony: Roche, Bayer, MSD, BMS, Pfizer, AstraZeneca; Travel / Accommodation / Expenses: Roche, MSD, BMS, AstraZeneca. L. Paz-Ares: Advisory / Consultancy: Roche, Lilly, Novartis, Pfizer, BMS, MSD, Takeda, AstraZeneca, Boehringer Ingelheim, Bayer, Janssen, Celgene; Honoraria (self): Roche, Lilly, Novartis, Pfizer, BMS, MSD, Amgen, Merck, Sanofi, Takeda, AstraZeneca, Boehringer Ingelheim, Bayer, Janssen, PharmaMar, Celgene. D.R. Spigel: Advisory / Consultancy: AbbVie (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Evelo Therapeutics (Inst); Foundation Medicine (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Illumina (Inst); Lilly (Inst); Research grant / Funding (institution): AbbVie (Inst); Acerta Pharma (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncolog; Travel / Accommodation / Expenses: AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Genzyme; Intuitive Surgical; Lilly; Merck; Pfizer; Purdue Pharma; Spectrum Pharmaceuticals; Sysmex. M. Thomas: Advisory / Consultancy: Novartis, Lilly, Pfizer, Bristol-Myers Squibb, Roche, AstraZeneca, Boehringer Ingelheim, MSD; Honoraria (self): Roche, Bristol-Myers Squibb, Lilly, AstraZeneca, Novartis, Pfizer, Boehringer Ingelheim, MSD; Research grant / Funding (self): Roche, BMS, MSD, AstraZeneca, Takeda. E.B. Garon: Advisory / Consultancy: Dracen, EMD Serono; Research grant / Funding (self): AstraZeneca, BMS, Eli Lilly, Genentech, Merck, Novartis, Neon, Iovance, Dynavax, Mirati. M. Leung: Shareholder / Stockholder / Stock options: Novartis; Full / Part-time employment: Novartis. J. Baum: Shareholder / Stockholder / Stock options: Novartis stock; Full / Part-time employment: Novartis. Spouse (Lauren Baum) – Abbot Laboratories. Z. Zewen: Full / Part-time employment: Novartis; Shareholder / Stockholder / Stock options: Novartis. B. Mookerjee: Full / Part-time employment: Novartis; Shareholder / Stockholder / Stock options: Novartis, GlaxoSmithKline, Incyte, AstraZeneca. J.C-H. Yang: Advisory / Consultancy: Boehringer Ingelheim, Eli Lilly, Bayer, Roche/Genentech, Chugai Pharmaceutical, MSD, Merck Serono, Pfizer, Novartis, Celgene, Merrimack, Yuhan Pharmaceuticals, BMS, Ono Pharmaceuticals, Daiichi-Sankyo, Hansoh Pharmaceuticals, Takeda Pharmaceuticals, Bluep; Honoraria (self): Boehringer Ingelheim, Eli Lilly, Bayer, Roche/Genentech, Chugai Pharmaceutical, MSD, Merck Serono, Pfizer, Novartis, Celgene, Merrimack, Yuhan Pharmaceuticals, BMS, Ono Pharmaceuticals, Daiichi-Sankyo, Hansoh Pharmaceuticals, Takeda Pharmaceuticals, Bluep; Leadership role: IASLC CME activity: Author/Board of Directors/Presenter/Reviewer. All other authors have declared no conflicts of interest." @default.
• W2990766679 created "2019-12-05" @default.
• W2990766679 creator A5012278970 @default.
• W2990766679 creator A5013149755 @default.
• W2990766679 creator A5013804417 @default.
• W2990766679 creator A5018054038 @default.
• W2990766679 creator A5022269577 @default.
• W2990766679 creator A5032325445 @default.
• W2990766679 creator A5032386417 @default.
• W2990766679 creator A5046765289 @default.
• W2990766679 creator A5050486105 @default.
• W2990766679 creator A5050787724 @default.
• W2990766679 creator A5052765751 @default.
• W2990766679 creator A5053546904 @default.
• W2990766679 creator A5060287300 @default.
• W2990766679 creator A5073474387 @default.
• W2990766679 creator A5084561034 @default.
• W2990766679 creator A5084791255 @default.
• W2990766679 creator A5085625374 @default.
• W2990766679 creator A5087836238 @default.
• W2990766679 creator A5087860798 @default.
• W2990766679 creator A5091393978 @default.
• W2990766679 date "2019-11-01" @default.
• W2990766679 modified "2023-10-18" @default.
• W2990766679 title "CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC" @default.
• W2990766679 doi "https://doi.org/10.1093/annonc/mdz437.056" @default.
• W2990766679 hasPublicationYear "2019" @default.
• W2990766679 type Work @default.
• W2990766679 sameAs 2990766679 @default.
• W2990766679 citedByCount "0" @default.
• W2990766679 crossrefType "journal-article" @default.
• W2990766679 hasAuthorship W2990766679A5012278970 @default.
• W2990766679 hasAuthorship W2990766679A5013149755 @default.
• W2990766679 hasAuthorship W2990766679A5013804417 @default.
• W2990766679 hasAuthorship W2990766679A5018054038 @default.
• W2990766679 hasAuthorship W2990766679A5022269577 @default.
• W2990766679 hasAuthorship W2990766679A5032325445 @default.
• W2990766679 hasAuthorship W2990766679A5032386417 @default.
• W2990766679 hasAuthorship W2990766679A5046765289 @default.
• W2990766679 hasAuthorship W2990766679A5050486105 @default.
• W2990766679 hasAuthorship W2990766679A5050787724 @default.
• W2990766679 hasAuthorship W2990766679A5052765751 @default.
• W2990766679 hasAuthorship W2990766679A5053546904 @default.
• W2990766679 hasAuthorship W2990766679A5060287300 @default.
• W2990766679 hasAuthorship W2990766679A5073474387 @default.
• W2990766679 hasAuthorship W2990766679A5084561034 @default.
• W2990766679 hasAuthorship W2990766679A5084791255 @default.
• W2990766679 hasAuthorship W2990766679A5085625374 @default.
• W2990766679 hasAuthorship W2990766679A5087836238 @default.
• W2990766679 hasAuthorship W2990766679A5087860798 @default.
• W2990766679 hasAuthorship W2990766679A5091393978 @default.
• W2990766679 hasBestOaLocation W29907666791 @default.
• W2990766679 hasConcept C126322002 @default.
• W2990766679 hasConcept C141071460 @default.
• W2990766679 hasConcept C142724271 @default.
• W2990766679 hasConcept C143998085 @default.
• W2990766679 hasConcept C204787440 @default.
• W2990766679 hasConcept C27081682 @default.
• W2990766679 hasConcept C2776256026 @default.
• W2990766679 hasConcept C2779134260 @default.
• W2990766679 hasConcept C2779725882 @default.
• W2990766679 hasConcept C2781228260 @default.
• W2990766679 hasConcept C71924100 @default.
• W2990766679 hasConceptScore W2990766679C126322002 @default.
• W2990766679 hasConceptScore W2990766679C141071460 @default.
• W2990766679 hasConceptScore W2990766679C142724271 @default.
• W2990766679 hasConceptScore W2990766679C143998085 @default.
• W2990766679 hasConceptScore W2990766679C204787440 @default.
• W2990766679 hasConceptScore W2990766679C27081682 @default.
• W2990766679 hasConceptScore W2990766679C2776256026 @default.
• W2990766679 hasConceptScore W2990766679C2779134260 @default.
• W2990766679 hasConceptScore W2990766679C2779725882 @default.
• W2990766679 hasConceptScore W2990766679C2781228260 @default.
• W2990766679 hasConceptScore W2990766679C71924100 @default.
• W2990766679 hasLocation W29907666791 @default.
• W2990766679 hasOpenAccess W2990766679 @default.
• W2990766679 hasPrimaryLocation W29907666791 @default.
• W2990766679 hasRelatedWork W1992839193 @default.
• W2990766679 hasRelatedWork W2127700366 @default.
• W2990766679 hasRelatedWork W2337227118 @default.
• W2990766679 hasRelatedWork W2978212681 @default.
• W2990766679 hasRelatedWork W2978318234 @default.
• W2990766679 hasRelatedWork W2978373166 @default.
• W2990766679 hasRelatedWork W2978687871 @default.
• W2990766679 hasRelatedWork W2978821371 @default.
• W2990766679 hasRelatedWork W2979118966 @default.
• W2990766679 hasRelatedWork W2979127504 @default.
• W2990766679 hasRelatedWork W2989665918 @default.
• W2990766679 hasRelatedWork W2989962636 @default.
• W2990766679 hasRelatedWork W2990424050 @default.
• W2990766679 hasRelatedWork W2990936758 @default.
• W2990766679 hasRelatedWork W2994869619 @default.
• W2990766679 hasRelatedWork W2995826615 @default.
• W2990766679 hasRelatedWork W2996109210 @default.
• W2990766679 hasRelatedWork W3033626340 @default.
• W2990766679 hasRelatedWork W3035499288 @default.
• W2990766679 hasRelatedWork W3165240783 @default.
• W2990766679 isParatext "false" @default.
• W2990766679 isRetracted "false" @default.
• W2990766679 magId "2990766679" @default.

• next